ZM 230487

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526584

CAS#: 155944-23-3

Description: ZM 230487 is a 5-lipoxygenase inhibitor.


Chemical Structure

img
ZM 230487
CAS# 155944-23-3

Theoretical Analysis

MedKoo Cat#: 526584
Name: ZM 230487
CAS#: 155944-23-3
Chemical Formula: C24H26FNO
Exact Mass: 411.1846
Molecular Weight: 411.4734
Elemental Analysis: C, 70.06; H, 6.37; F, 4.62; N, 3.40; O, 15.55

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ICI-230487; ICI230487; ICI 230487; ZM 230487; ZM-230487; ZM230487

IUPAC/Chemical Name: 1-ethyl-6-((3-fluoro-5-(4-methoxytetrahydro-2H-pyran-4-yl)phenoxy)methyl)quinolin-2(1H)-one

InChi Key: ZROVOGSXAWNIQB-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H26FNO4/c1-3-26-22-6-4-17(12-18(22)5-7-23(26)27)16-30-21-14-19(13-20(25)15-21)24(28-2)8-10-29-11-9-24/h4-7,12-15H,3,8-11,16H2,1-2H3

SMILES Code: O=C1N(CC)C2=C(C=C(COC3=CC(C4(OC)CCOCC4)=CC(F)=C3)C=C2)C=C1

Appearance: White to light yellow solid powder.

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 411.4734 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Teixeira MM, Hellewell PG. Effect of a 5-lipoxygenase inhibitor, ZM 230487, on cutaneous allergic inflammation in the guinea-pig. Br J Pharmacol. 1994 Apr;111(4):1205-11. PubMed PMID: 8032607; PubMed Central PMCID: PMC1910165.

2: Werz O, Szellas D, Henseler M, Steinhilber D. Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Mol Pharmacol. 1998 Aug;54(2):445-51. PubMed PMID: 9687587.

3: Trandafir CC, Nishihashi T, Wang A, Murakami S, Ji X, Kurahashi K. Participation of vasopressin in the development of cerebral vasospasm in a rat model of subarachnoid haemorrhage. Clin Exp Pharmacol Physiol. 2004 Apr;31(4):261-6. PubMed PMID: 15053824.

4: Werz O, Schneider N, Brungs M, Sailer ER, Safayhi H, Ammon HP, Steinhilber D. A test system for leukotriene synthesis inhibitors based on the in-vitro differentiation of the human leukemic cell lines HL-60 and Mono Mac 6. Naunyn Schmiedebergs Arch Pharmacol. 1997 Oct;356(4):441-5. PubMed PMID: 9349629.

5: Negro JM, Miralles JC, Ortiz JL, Funes E, García A. Biosynthesis inhibitors for leukotrienes in bronchial asthma. Allergol Immunopathol (Madr). 1997 Jul-Aug;25(4):209-16. Review. PubMed PMID: 9269512.

6: Ji X, Nishihashi T, Trandafir CC, Wang A, Shimizu Y, Kurahashi K. Pharmacological nature of nicotine-induced contraction in the rat basilar artery: involvement of arachidonic acid metabolites. Eur J Pharmacol. 2007 Dec 22;577(1-3):109-14. Epub 2007 Aug 14. PubMed PMID: 17765890.

7: Wang A, Nishihashi T, Trandafir CC, Murakami S, Ji X, Shimizu Y, Kurahashi K. Involvement of endothelial cyclo-oxygenase metabolites in noradrenaline-induced contraction of rat coronary artery. Clin Exp Pharmacol Physiol. 2005 Aug;32(8):628-32. PubMed PMID: 16120189.

8: Teixeira MM, Fairbairn SM, Norman KE, Williams TJ, Rossi AG, Hellewell PG. Studies on the mechanisms involved in the inflammatory response in a reversed passive Arthus reaction in guinea-pig skin: contribution of neutrophils and endogenous mediators. Br J Pharmacol. 1994 Dec;113(4):1363-71. PubMed PMID: 7889293; PubMed Central PMCID: PMC1510534.

9: Anderson GI, MacQuarrie R, Osinga C, Chen YF, Langman M, Gilbert R. Inhibition of leukotriene function can modulate particulate-induced changes in bone cell differentiation and activity. J Biomed Mater Res. 2001;58(4):406-14. PubMed PMID: 11410899.

10: Bode H, Schmitz H, Fromm M, Scholz P, Riecken EO, Schulzke JD. IL-1beta and TNF-alpha, but not IFN-alpha, IFN-gamma, IL-6 or IL-8, are secretory mediators in human distal colon. Cytokine. 1998 Jun;10(6):457-65. PubMed PMID: 9632533.

11: Fischer L, Szellas D, Rådmark O, Steinhilber D, Werz O. Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J. 2003 May;17(8):949-51. Epub 2003 Mar 28. PubMed PMID: 12670876.

12: Vicente AM, Guillén MI, Alcaraz MJ. Modulation of haem oxygenase-1 expression by nitric oxide and leukotrienes in zymosan-activated macrophages. Br J Pharmacol. 2001 Jul;133(6):920-6. PubMed PMID: 11454666; PubMed Central PMCID: PMC1572852.

13: Teixeira MM, Lindsay MA, Giembycz MA, Hellewell PG. Role of arachidonic acid in leukotriene B(4)-induced guinea-pig eosinophil homotypic aggregation. Eur J Pharmacol. 1999 Nov 19;384(2-3):183-90. PubMed PMID: 10611440.

14: Bennett G, al-Rashed S, Hoult JR, Brain SD. Nerve growth factor induced hyperalgesia in the rat hind paw is dependent on circulating neutrophils. Pain. 1998 Sep;77(3):315-22. PubMed PMID: 9808357.

15: Macari DM, Teixeira MM, Hellewell PG. Priming of eosinophil recruitment in vivo by LPS pretreatment. J Immunol. 1996 Aug 15;157(4):1684-92. PubMed PMID: 8759756.

16: Walsh DT, Weg VB, Williams TJ, Nourshargh S. Substance P-induced inflammatory responses in guinea-pig skin: the effect of specific NK1 receptor antagonists and the role of endogenous mediators. Br J Pharmacol. 1995 Apr;114(7):1343-50. PubMed PMID: 7541689; PubMed Central PMCID: PMC1510297.

17: Beno DW, Mullen J, Davis BH. Lipoxygenase inhibitors block PDGF-induced mitogenesis: a MAPK-independent mechanism that blocks fos and egr. Am J Physiol. 1995 Mar;268(3 Pt 1):C604-10. PubMed PMID: 7900768.

18: Kusner EJ, Buckner CK, Dea DM, DeHaas CJ, Marks RL, Krell RD. The 5-lipoxygenase inhibitors ZD2138 and ZM230487 are potent and selective inhibitors of several antigen-induced guinea-pig pulmonary responses. Eur J Pharmacol. 1994 May 23;257(3):285-92. PubMed PMID: 7522174.

19: Trandafir CC, Nishihashi T, Ji X, Wang A, Kurahashi K. Cysteinyl leukotrienes and leukotriene B mediate vasoconstriction to arginine vasopressin in rat basilar artery. Clin Exp Pharmacol Physiol. 2005 Dec;32(12):1027-33. PubMed PMID: 16445567.

20: Eilertsen KE, Olsen JO, Østerud B. Ex-vivo regulation of endotoxin-induced tissue factor in whole blood by eicosanoids. Blood Coagul Fibrinolysis. 2003 Jan;14(1):41-8. PubMed PMID: 12544727.